0000000000312176

AUTHOR

Michel Velten

showing 16 related works from this author

Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

2019

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines- are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these t…

OncologyMaleSurvival030232 urology & nephrologyDiseaseCarcinoma; Community network; Europe; Germ cell and embryonal; Neoplasms; Penis neoplasms; Rare diseases; Squamous cell; Survival; Tertiary care centres; Testicular neoplasms; Surgery; Oncology0302 clinical medicineNeoplasmsEpidemiologyTesticular neoplasmReferral and ConsultationPenis neoplasmsCarcinoma ; Community network ; Europe ; Germ cell and embryonal ; Neoplasms ; Penis neoplasms ; Rare diseases ; Squamous cell ; Survival ; Tertiary care centres ; Testicular neoplasmsGeneral MedicineNeoplasms Germ Cell and EmbryonalTertiary care centreRare diseasesSurvival RateEuropeOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellHumanmedicine.medical_specialtyTesticular neoplasmsPenile squamous cell carcinomaGerm cell and embryonalCommunity networkSocio-culturaleCancer Care FacilitiesTertiary care centres03 medical and health sciencesPenis neoplasmRare DiseaseInternal medicinemedicineCarcinomaHumansPenile NeoplasmsNeoplasm StagingPenis Neoplasmsbusiness.industryCancer Care FacilitieSquamous cellCarcinomaLymphatic Metastasimedicine.diseaseTesticular germ cellAdult lifePenile NeoplasmProper treatmentNeoplasmLymph Node ExcisionSurgerybusinessDelivery of Health Care
researchProduct

Epidemiology of rare cancers and inequalities in oncologic outcomes

2019

Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year surv…

0301 basic medicineMaleSettore MED/06 - Oncologia Medica0302 clinical medicineNeoplasmsEpidemiologyPrevalenceEurope ; Population-based cancer registry ; Rare cancersChildeducation.field_of_studyRelative survivalIncidence (epidemiology)IncidenceGeneral MedicineMiddle AgedSurvival RateEuropeHealthcare DisparitieOncology030220 oncology & carcinogenesisChild PreschoolFemaleHumanAdultmedicine.medical_specialtyAdolescentEurope; Population-based cancer registry; Rare cancers; Surgery; OncologyPopulationSocio-culturaleEurope Population-based cancer registry Rare cancers03 medical and health sciencesYoung AdultRare DiseasesAge DistributionRare DiseasemedicineHumansRare cancersHealthcare DisparitiesSex DistributioneducationPopulation-based cancer registrySurvival rateAgedbusiness.industryPublic healthInfant NewbornCancerRare cancerInfantmedicine.diseaseClinical trial030104 developmental biologyNeoplasmSurgerybusinessDemography
researchProduct

Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Informatio…

2018

List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, En…

MaleCàncer en els infantsTime FactorsCancer in children0302 clinical medicineRisk FactorsNeoplasms030212 general & internal medicineRegistriesAge of OnsetChildmedia_commoneducation.field_of_studyCancer in adolescenceIncidence (epidemiology)Incidence3. Good healthEuropeOncology030220 oncology & carcinogenesisRegional studiesChild PreschoolFemale2730 OncologyAdolescentPopulationChildhood cancerSocio-culturale610 Medicine & healthRisk AssessmentArticle03 medical and health sciencesYoung AdultAge DistributionSDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansCàncer en els adolescentsEuropean unioneducationbusiness.industryInfant NewbornCancerInfantHealth Status Disparities10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseasePopulation based studyCancer incidencebusinessDemography
researchProduct

Treatment challenges in and outside a network setting: Head and neck cancers.

2019

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lea…

0301 basic medicinemedicine.medical_specialtySocio-culturaleSocial issuesMultidisciplinary team03 medical and health sciencesTherapeutic approach0302 clinical medicineRare DiseasesMultidisciplinary approachmedicineHumansAdverse effectIntensive care medicineHead and neck cancerReferral and ConsultationPatient Care TeamEuropean reference networks joint action of rare cancers ; Head and neck cancer ; Multidisciplinary team ; Rare diseasebusiness.industryHead and Neck NeoplasmHead and neck cancerEuropean reference networks joint action of rare cancersGeneral MedicineMultidisciplinary teammedicine.diseaseEurope030104 developmental biologyClinical researchOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisEuropean reference networks joint action of rare cancerSurgerybusinessEuropean reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease; Surgery; OncologyRare diseaseDelivery of Health CareRare diseaseHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Factors Associated With Fatigue After Surgery in Women With Early-Stage Invasive Breast Cancer

2013

Abstract Learning Objectives Describe the effect of worsening fatigue after breast cancer surgery on physical functioning and psychological distress. Better identify women at risk for developing cancer-related fatigue. Direct target interventions to patients most in need. Purpose. Fatigue is one of the most frequent symptoms in patients with cancer. However, the precise determinants of fatigue are still unknown. This study was conducted to investigate factors correlated with cancer-related fatigue before surgery and just before subsequent adjuvant therapy. Methods. Patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Can…

MESH: FatigueCancer ResearchMultivariate analysisMESH: Lymph NodesDisease0302 clinical medicineMESH: Aged 80 and overQuality of lifeSurveys and Questionnaires030212 general & internal medicineNeoplasm Metastasisskin and connective tissue diseasesFatigueAged 80 and overMESH: AgedMESH: Middle AgedMESH: Neoplasm StagingMiddle Aged3. Good healthOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisAnxietyMarital statusFemalemedicine.symptomAdultmedicine.medical_specialtyBreast Neoplasms03 medical and health sciencesBreast cancerAdjuvant therapymedicineHumansNeoplasm InvasivenessMESH: Surveys and QuestionnairesAgedNeoplasm StagingMESH: Humansbusiness.industryCancerMESH: Quality of LifeMESH: AdultMESH: Neoplasm Invasivenessmedicine.diseaseMESH: Neoplasm MetastasisSurgeryQuality of Life[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieLymph NodesbusinessMESH: FemaleMESH: Breast Neoplasms
researchProduct

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

2019

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

Liver metastasemedicine.medical_specialtyPathologySocio-culturale03 medical and health sciencesLiver metastasesRare Diseases0302 clinical medicineLiver metastases ; Neuroendocrine tumours ; Pancreas ; Rare cancersNeuroendocrine tumoursMultidisciplinary approachRare DiseaseNeuroendocrine tumourHumansMedicinePancreaRare cancersPrecision MedicineIntensive care medicinePancreasLiver metastases Neuroendocrine tumours Pancreas Rare cancersPatient Care Teambusiness.industryPancreatic NeoplasmRare cancerGeneral MedicinePancreatic NeoplasmsSurvival RateNeuroendocrine TumorsLiver metastases; Neuroendocrine tumours; Pancreas; Rare cancers; Surgery; OncologyOncology030220 oncology & carcinogenesisMandate030211 gastroenterology & hepatologySurgerybusinessNeuroendocrine TumorDelivery of Health CareHuman
researchProduct

Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions afte…

2013

In the French national health insurance information system (SNIIR-AM), routine records of health claimed reimbursements are linked to hospital admissions for the whole French population. The main focus of this work is the usability of this system for vaccine safety assessment programme. Self-controlled case series analyses were performed using an exhaustive SNIIR-AM extraction of French children aged less than 3 years, to investigate the relationship between MMR immunization and children hospitalizations for febrile convulsions, a well-documented rare adverse event, over 2009-2010. The results suggest a significant increase of febrile convulsions during the 6-11 days period following any MM…

RiskPediatricsmedicine.medical_specialtyNational Health ProgramsMeasles-Mumps-Rubella VaccinePopulationRate ratioSeizures FebrilePneumococcal conjugate vaccine03 medical and health sciences0302 clinical medicine030225 pediatricsProduct Surveillance PostmarketingAdverse Drug Reaction Reporting SystemsHumansMedicine030212 general & internal medicineeducationAdverse effectImmunization ScheduleComputingMilieux_MISCELLANEOUSeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantICD-103. Good healthHospitalizationVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular Medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusiness[STAT.ME]Statistics [stat]/Methodology [stat.ME]Measles-Mumps-Rubella Vaccinemedicine.drug
researchProduct

The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study.

2008

International audience; Survival data on female invasive breast cancer with 9-year follow-up from five French cancer registries were analysed by logistic regression for prognostic factors of cancer stage. The Kaplan-Meier method and log-rank test were used to estimate and compare the overall survival probability at 5 and 7 years, and at the endpoint. The Cox regression model was used for multivariate analysis. County of residence, age group, occupational status, mammographic surveillance, gynaecological prevention consultations and the diagnosis mammography, whether within a screening framework or not, were independent prognostic factors of survival. Moreover, for the same age group, and on…

OncologyCancer ResearchEpidemiologyMESH : AgedMESH : Breast NeoplasmsLogistic regressionsurvival analysis0302 clinical medicineMESH: Aged 80 and overMESH : Population SurveillanceMESH : Socioeconomic FactorsMedicineMESH : Female030212 general & internal medicineAged 80 and overMESH: AgedMESH: Middle Agedmedicine.diagnostic_testCarcinoma Ductal Breast[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: European Continental Ancestry GroupMESH: Follow-Up StudiesMiddle AgedMESH : AdultMESH : Survival Rate3. Good healthSurvival RateOncology030220 oncology & carcinogenesisPopulation SurveillanceFemalemass screeningAdultmedicine.medical_specialtyMESH: Socioeconomic FactorsMESH: Survival RatemammographyMESH: MammographyBreast NeoplasmsWhite PeopleMESH: Population SurveillanceMESH : European Continental Ancestry Group03 medical and health sciencesBreast cancerbreast neoplasmInternal medicineMammographyHumansMESH : MammographyMESH : Middle AgedMESH: Mass ScreeningMESH : Aged 80 and overSurvival rateMass screeningSurvival analysisAgedGynecologyMESH : Mass ScreeningMESH: Humansbusiness.industryProportional hazards modelMESH : HumansMESH : Carcinoma Ductal BreastCancerMESH: AdultMESH : Follow-Up Studiesmedicine.diseaseMESH: Carcinoma Ductal BreastSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiesocio-economic factors[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleMESH: Breast NeoplasmsFollow-Up Studies
researchProduct

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

2017

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMI…

0301 basic medicineMesotheliomamedicine.medical_specialtyInternational CooperationPleural NeoplasmsMEDLINESocio-culturaleContext (language use)Translational researchDiseaseSocial Networking03 medical and health sciences0302 clinical medicineMultidisciplinary approachMedicineHumansMesotheliomaPleural NeoplasmIntensive care medicinebusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseClinical trialEuropeSurvival Rate030104 developmental biologyClinical researchOncology030220 oncology & carcinogenesisSurgery; OncologySurgerybusinessDelivery of Health Caremesothelioma thymic tumours clinical trialsHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients

2014

Few studies have investigated rectal cancer management at the population level. We compared how rectal cancers diagnosed in Italy (2003-2005) and France (2005) were managed, and evaluated the extent to which management adhered to European guidelines.Samples of 3938 Italian and 2287 French colorectal cancer patients were randomly extracted from 8 and 12 cancer registries respectively. Rectal cancer patients (860 Italian, 559 French) were analysed. Logistic regression models estimated odds ratios (ORs) of being treated with curative intent, receiving sphincter-saving surgery, and receiving preoperative radiotherapy.Similar proportions of Italian and French patients were treated with curative …

Malemedicine.medical_specialtyPreoperative radiotherapyPopulation levelColorectal cancer[SDV]Life Sciences [q-bio]Anal CanalAdenocarcinomaLogistic regressionInternal medicinemedicineHumansComputingMilieux_MISCELLANEOUSAgedAged 80 and overHepatologybusiness.industryRectal NeoplasmsGastroenterologyCancerOdds ratioMiddle Agedmedicine.diseaseNeoadjuvant Therapy3. Good healthSurgeryCancer registryPopulation based studyItalyPractice Guidelines as TopicLymph Node ExcisionFemaleRadiotherapy AdjuvantFranceGuideline AdherencebusinessOrgan Sparing Treatments
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

2015

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of diseases that are known to carry a considerable risk of second primary cancer (SPC). However, little attention has been paid to SPC risk assessment according to NHL subtypes. Data from 10 French population-based cancer registries were used to establish a cohort of 7546 patients with a first diagnosis of NHL (eight subtypes) between 1989 and 2004. Standardized incidence ratios (SIRs) of metachronous SPC were estimated. Among the 7546 patients diagnosed with a NHL, the overall SPC risk was 25% higher than that in the reference population (SIR = 1.25, 95% confidence interval 1.15–1.36). In univariate analysis, the SPC risk differed…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyanimal structuresMultivariate analysisAdolescentPopulationRisk AssessmentCohort StudiesYoung Adultimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiologymedicineHumansRegistrieseducationChildAgedAged 80 and overUnivariate analysiseducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinfungiAge FactorsInfant NewbornCancerInfantNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseOncologyChild PreschoolPopulation SurveillanceCohortImmunologyFemaleFranceRisk assessmentbusinessFollow-Up StudiesLeukemialymphoma
researchProduct

A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

2010

Summary Background Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions. The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers. Methods The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries. Data were collected using a standardized procedure. Results Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.…

MaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPerforation (oil well)Population[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaSampling Studies[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistries030212 general & internal medicineStage (cooking)educationAgedAged 80 and overPatient Care TeamChemotherapyeducation.field_of_studybusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgeryClinical trialChemotherapy AdjuvantIntestinal Perforation030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisPopulation studyFemaleFrancebusinessIntestinal Obstruction
researchProduct

Second Cancer Incidence Among Chronic Lymphocytic Leukemia (CLL) Patients: A French Population-Based Study

2014

Abstract Introduction. The risk of developing a second primary cancer (SPC) is increased in patients with CLL. The mechanisms explaining this association could be related to lifestyle, environment, host factors or interactions or other influences. We conducted an epidemiological study based on 10 French registries and evaluated the risk of developing SPC in patients with CLL. Methods. Data from French population-based registries were used to establish a cohort of all patients diagnosed with a first cancer between 1989 and 2004 and followed-up until December 31, 2007. The person-year approach was used to estimate Standardized Incidence Ratios (SIRs) and Excess Absolute Risks (EARs) of metach…

Oncologymedicine.medical_specialtyeducation.field_of_studyAcute leukemiabusiness.industryIncidence (epidemiology)ImmunologyPopulationAbsolute risk reductionCancerCell BiologyHematologyDiseasemedicine.diseaseBiochemistryInternal medicineEpidemiologyCohortImmunologymedicineeducationbusinessBlood
researchProduct

Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods

2013

Net survival, the survival which might occur if cancer was the only cause of death, is a major epidemiological indicator required for international or temporal comparisons. Recent findings have shown that all classical methods used for routine estimation of net survival from cancer-registry data, sometimes called "relative-survival methods," provide biased estimates. Meanwhile, an unbiased estimator, the Pohar-Perme estimator (PPE), was recently proposed. Using real data, we investigated the magnitude of the errors made by four "relative-survival" methods (Ederer I, Hakulinen, Ederer II and a univariable regression model) vs. PPE as reference and examined the influence of time of follow-up,…

AdultMaleCancer ResearchLung NeoplasmsAdolescent[SDV]Life Sciences [q-bio]Breast NeoplasmsRisk Assessment03 medical and health sciencesAge Distribution0302 clinical medicineBreast cancerBiasBias of an estimatorRisk FactorsCause of DeathNeoplasmsStatisticsmedicineHumansRegistriesThyroid Neoplasms030212 general & internal medicineSurvival analysisAgedMathematicsEstimationModels StatisticalRelative survivalIncidenceAge FactorsProstatic NeoplasmsCancerEstimatorRegression analysisMiddle AgedPrognosismedicine.diseaseHodgkin DiseaseSurvival Analysis3. Good healthOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleFranceColorectal Neoplasms
researchProduct